Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/20/2009

risks that our expense reductions will not be as large as we expect; risks that the restructured operations for exenatide or our sales force will not produce the results we expect; and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA or SYMLIN. These and additional risks and uncertainties are described more fully in the Company's recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.

                         (Financial information to follow)


                           AMYLIN PHARMACEUTICALS, INC.

                       CONSOLIDATED STATEMENTS OF OPERATIONS
                       (in thousands, except per share data)
                                  (unaudited)

                                       Quarter ended      Nine months ended
                                        September 30,        September 30,
                                       2009      2008       2009      2008
                                       ----      ----       ----      ----
    Revenues:
      Net product sales             $192,887  $201,364   $569,716   $580,420
      Revenues under
       collaborative agreements       18,348    16,998     44,565     57,198
                                      ------    ------     ------     ------
    Total revenues                   211,235   218,362    614,281    637,618

    Costs and expenses:
      Cost of goods sold              22,624    23,395     65,549     70,101
      Selling, general and
        administrative                80,088    99,676    259,696    309,007
      Research and development        52,660    73,466    176,280    226,073
      Collaborative profit sharing    78,265    80,567    227,481    229,418
      Restructuring                        -         -     11,376          -
                        
'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  Heated dialogue in recent months about ... cancer treatments to Gilead,s new hepatitis C drug Harvoni® ... world questioning what it means to put a price ... And while drug pricing is one of the ... both a general business and ethical standpoint – it ...
(Date:11/21/2014)... , Nov. 21, 2014 ... the European Medicines Agency (EMA) has granted ... company,s lead product candidate, for the treatment ... a rare, severely disabling genetic disease characterized ... swelling (flare-ups) and new abnormal bone formation. ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... , Chief Executive Officer, will be presenting at the 26 ... York Palace Hotel in New York . ... at 2:00 PM ET. In addition, Mr. Krakauer and ... for separate one-on-one meetings during the day. ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
... IRIDEX Corporation (NASDAQ: IRIX ) today announced that it ... after the market closes on Thursday, March 1, 2012. ... a conference call with the investment community at 5:00 ... 2012 to discuss the results of the quarter and ...
... Medical Corp.,s (Nasdaq Market: ESMC) subsidiary,  Sonomed Escalon™ announced ... AXIS™ Image Management System at the recent World Ophthalmology ... Matthew Carnevale, Chief Technical Officer, stated that ... ophthalmic diagnostic imaging management, and provides an entirely new ...
Cached Medicine Technology:Sonomed Escalon™ Announces Release of AXIS™ iPad App 2Sonomed Escalon™ Announces Release of AXIS™ iPad App 3
(Date:11/22/2014)... 2014 (HealthDay News) -- Those air-blown hand dryers in ... paper towels, a new study suggests. British researchers ... of volunteers in order to simulate poorly washed hands. ... dryers or paper towels to dry their hands. ... amounts of germs around both types of dryers than ...
(Date:11/22/2014)... Amy Norton HealthDay Reporter ... live in nursing homes may commonly deal with aggressive or ... The study of 10 centers in New York state found ... percent of residents were involved in some type of incident ... verbal clash, with someone yelling or cursing at another resident. ...
(Date:11/21/2014)... Lauderdale, FL (PRWEB) November 21, 2014 Body ... services announced that it accepts Spafinder massage gift cards ... and in room hotel massage in all service areas including ... you don't have to go to the spa at all ... Owner and Founder of Body Well. "We may not be ...
(Date:11/21/2014)... THURSDAY, Nov. 20, 2014 (HealthDay News) -- Certain genes ... in up to a fifth of people with type ... has long been pondered by doctors working with diabetic ... have been under the impression that exercise helps decrease ... Dr. Maria Pena, director of the Center for Weight ...
(Date:11/21/2014)... 2014 MLF Biotech, Inc. has developed ... Liv-Pro® Probiotics for Pets helps maintain digestive health and ... pet's intestinal flora after it experiences a period of ... Probiotics for Pets is a proprietary blend of pure ... live active bacteria strains that are safe and effective ...
Breaking Medicine News(10 mins):Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 3Health News:Body Well Mobile Massage Announces Acceptance of Spafinder Gift Cards for In Home Massage, Hotel Massage for Travelers 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 3Health News:MLF Biotech Introduces Liv-Pro Probiotics for Pets 2
... Nov. 16 Blue Water Spa, a Raleigh NC Day Spa ... anniversary party and Raleigh food drive. Guests who donate frozen turkeys ... will receive a $10,000 spa gift certificate for luxury spa services. ... be on hand Wed. November 18 and Saturday December 12 to ...
... , MISSION VIEJO, Calif., Nov. ... the parent company of the Ensign(TM) group of skilled nursing, ... that a group of its real estate holding subsidiaries has ... to secure a $40 million five-year term loan from GE ...
... ... physics, unification theory and experiments in quantum mechanics - it says there is no ... space or in time. This could change science, medicine, religion, economics; and create world peace, ... ...
... , ... quickly becoming the most widely used resource for consumers looking for a top doctor in their ... New York, NY (PRWEB) November ... of the many dating sites and search through endless profiles until they find their match. ...
... ... Trendy Socks for Kids who Wear Ankle-Foot Orthoses (AFOs) , ... Westchester, NY (PRWEB) November 16, 2009 -- Ross Daniel ... its marketplace debut and the launch of “Cool Clothes for Toes,” the first creatively styled ...
... ... Dishler Laser Institute announced today that Dr. Jon Dishler has been ... of the United States for 2009. The list of leading Laser Eye ... issue of Forbes Magazine.,Internationally recognized, leader of numerous FDA laser vision trials, ...
Cached Medicine News:Health News:Raleigh Day Spa, Blue Water Spa, Raffles Off $10,000 in Day Spa Packages for Contributing to Raleigh Food Drive 2Health News:The Ensign Group Secures $40 Million Loan From GE Capital, Healthcare Financial Services 2Health News:The Ensign Group Secures $40 Million Loan From GE Capital, Healthcare Financial Services 3Health News:New View Of Reality (In Printed Book Form) That Combines Einstein And Quantum Mechanics, And Fills The World With Miracles 2Health News:New View Of Reality (In Printed Book Form) That Combines Einstein And Quantum Mechanics, And Fills The World With Miracles 3Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 3Health News:Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine 2Health News:Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine 3
... The BD Macro-Vue RPR (Rapid ... and Tear-drop Tests are nontreponemal testing ... syphilis described in A Manual of ... in this manual are the most ...
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
Enzyme Immunoassay for the quantitative ( qualitative 0020, on request) determination of IgG Class antibodies to Rubella virus....
Donor Screen & Confirmation Kit...
Medicine Products: